Salarius Pharmaceuticals (NASDAQ:SLRX) Cut to “Sell” at Wall Street Zen

by · The Cerbat Gem

Wall Street Zen cut shares of Salarius Pharmaceuticals (NASDAQ:SLRX – Free Report) from a hold rating to a sell rating in a report published on Saturday morning.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Salarius Pharmaceuticals in a research note on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Sell”.

Check Out Our Latest Research Report on SLRX

Salarius Pharmaceuticals Stock Performance

Shares of SLRX stock opened at $0.54 on Friday. The company has a market capitalization of $3.14 million, a PE ratio of -0.02 and a beta of 0.33. Salarius Pharmaceuticals has a 52-week low of $0.51 and a 52-week high of $108.00. The business’s fifty day moving average is $1.29 and its 200 day moving average is $5.52.

Salarius Pharmaceuticals (NASDAQ:SLRX – Get Free Report) last posted its earnings results on Friday, November 14th. The company reported ($1.81) EPS for the quarter, topping the consensus estimate of ($33.60) by $31.79.

Salarius Pharmaceuticals Company Profile

(Get Free Report)

Salarius Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that target epigenetic and post‐translational modification pathways in cancer. The company’s lead candidate, seclidemstat (SP‐2577), is designed to inhibit lysine‐specific demethylase 1 (LSD1) and modulate the tumor microenvironment, with a primary focus on treating Ewing sarcoma, a rare and aggressive bone and soft tissue cancer affecting children and young adults.

Further Reading